<DOC>
	<DOCNO>NCT00195897</DOCNO>
	<brief_summary>Anthracycline-based chemotherapy key point treatment patient Hodgkin 's non-Hodgkin 's lymphoma . However , cumulative dos limit cardiotoxicity , result mark leave ventricular function impairment may lead heart failure . The standard clinical approach monitoring anthracycline cardiotoxicity base cardiac function monitoring use echocardiography radionuclide angiography . The aim study evaluate usefulness biochemical marker cardiac injury ( troponin NT-proBNP ) structural change cardiac MR predict anthracycline cardiotoxicity .</brief_summary>
	<brief_title>Early Assessment Anthracycline-induced Cardiotoxicity ( CARDIOTOX )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Histologically proven lymphoma ( Hodgkin 's nonHodgkin 's ) Age &gt; 18 y/o &lt; 70 y/o WHO score &lt; = 2 Life expectancy &gt; 6 mo Left ventricular ejection fraction &gt; 50 % Informed consent Previous chemotherapy use anthracyclines History radiation therapy History congestive heart failure History chronic renal insufficiency Contra indication MR examination Atrial fibrillation significant arrhythmia Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Anthracyclines</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Radionuclide</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Troponin</keyword>
	<keyword>Natriuretic Peptide , Brain</keyword>
</DOC>